Our study was to elucidate the mechanisms whereby BMS-345541 (BMS, a specific IjB kinase b inhibitor) inhibits the repair of DNA double-strand breaks (DSBs) and evaluate whether BMS can sensitize MCF-7 breast cancer cells (MCF-7 cells) to ionizing radiation (IR) in an apoptosis-independent manner. In this study, MCF-7 cells were exposed to IR in vitro and in vivo with or without pretreatment of BMS. The effects of BMS on the repair of IR-induced DSBs by homologous recombination (HR) and non-homologous end-joining (NHEJ) were analyzed by the DR-GFP and EJ5-GFP reporter assays and IR-induced c-H2AX, 53BP1, Brca1 and Rad51 foci assays. The mechanisms by which BMS inhibits HR were examined by microarray analysis and quantitative reverse transcription PCR. The effects of BMS on the sensitivity of MCF-7 cells to IR were determined by MTT and clonogenic assays in vitro and tumor growth inhibition in vivo in a xenograft mouse model. The results showed that BMS selectively inhibited HR repair of DSBs in MCF-7 cells, most likely by down-regulation of several genes that participate in HR. This resulted in a significant increase in the DNA damage response that sensitizes MCF-7 cells to IRinduced cell death in an apoptosis-independent manner.
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INTRODUCTION
It has been well established that ionizing radiation (IR) kills cancer cells primarily by induction of DNA doublestrand breaks (DSBs) and efficient repair of DSBs is required for the clonogenic survival of irradiated cells (1, 2) . Our recent studies showed that IjB kinase b (IKKb), but not IKKa, can regulate the repair of IR-induced DSBs in a nuclear factor jB (NF-jB) RELA-independent manner (3). This finding suggests that specific IKKb inhibitors can be exploited as novel therapeutic agents to increase the sensitivity of tumor cells to IR. Since IKKb inhibitors can inhibit not only DSB repair but also NF-jB mediated induction of anti-apoptotic proteins (4-6), they are potentially more advantageous than other DSB repair inhibitors such as ATM and DNA-PK inhibitors to sensitize tumor cells to IR.
BMS is a potent and specific inhibitor of IKKb (7) . It binds to an allosteric binding site on the IKKb catalytic subunits and can inhibit IjBa phosphorylation and degradation and therefore NF-jB activation induced by diverse stimuli (7) . Our previous studies demonstrated that BMS can sensitize MCF-7 breast cancer cells (MCF-7 cells) to IR in vitro at least in part by inhibition of DSB repair (3). However, the mechanisms by which BMS inhibits DSBs are unknown, and whether it can sensitize tumor cells to IR in vivo has not been tested. Therefore, in the present study we elucidate the mechanisms whereby BMS inhibits the repair of DSBs and evaluate whether BMS can sensitize MCF-7 cells to IR not only in vitro but also in a mouse xenograft tumor model. Our investigations revealed that BMS selectively inhibited homologous recombinational (HR) repair of DSBs in MCF-7 cells, probably by down-regulation of several genes that participate in HR, which led to a significant increase in the DNA damage response (DDR) that sensitizes MCF-7 cells to IR-induced cell death in an apoptosis-independent manner. Furthermore, BMS treatment sensitized MCF-7 xenograft tumors to radiation therapy in vivo in an association with a significant delay in the repair of IR-induced DSBs. BMS has been shown to be relatively safe and appears not to cause significant normal tissue damage in vivo (8) (9) (10) . These findings and our current data highlight the therapeutic potential of BMS as a novel tumor radiosensitizer that can be used to selectively increase the responsiveness of tumors to IR.
MATERIALS AND METHODS

Cell Lines and Reagents
MCF-7 cells and H1299 and H1648 human lung cancer cell lines were obtained from ATCC (Manassas, VA) and were maintained in Dulbecco's modified Eagle's minimal (DMEM) supplemented with 10% fetal bovine serum (HyClone, Logan, UT), penicillin (100 U/ml) and streptomycin (100 lg/ml) in a humidified incubator (95% air/5% CO 2 ) at 378C. IKKb knockdown (IKK-b (-)) MCF-7 cells and MCF-7 cells stably transfected with a dominant-negative mutant IjBa (mIjBa or IjBa A32/36) were generated and obtained as we previously described (3). BMS-345541 (BMS), Hoechst-33342 (Hoe) and propidium iodide (PI) were purchased from Sigma-Aldrich (St. Louis, MO).
Irradiation of Cells
Cells were exposed to various doses of IR in a J. L. Shepherd Model Mark I
137
Cesium c-irradiator (J. L. Shepherd, Glendale, CA) at a dose rate of 1.84 Gy/min. Cells were irradiated on a rotating platform.
NF-jB RelA DNA-binding Activity Assay and Quantitative Real-Time PCR (qRT-PCR)
All of these assays were carried out as described previously (3) . The sequences for all of the primers used in the qRT-PCR analyses are listed in Supplementary Table 1 (http://dx.doi.org/10.1667/RR3034.1. S1).
Immunofluorescence Staining
Cells grown on a 4-chamber CultureSlide (BD Falcon, Bedford, MA) after various treatments were fixed, permeabilized and stained as previously described (3 
Neutral Comet Assay
Cells were either sham-irradiated or exposed to 15 Gy IR 1 h after pretreatment with vehicle or 5 lM BMS. Cells were collected at various times after irradiation and processed for neutral comet assay using a CometAssay t kit from Trevigen (Gaithersburg, MD) per the manufacturer's protocol. Approximately 100 nucleus images were captured for each slide and processed by a Zeiss Axio Observer.Z1 microscope as described before (3) . The tail moments from the cells were measured by the TriTek CometScoree software (Version 1.5.2.6; TriTek Corporation, Summerduck, VA).
HR Assay
HR was measured in MCF7/DR-GFP cells, according to the previous publication (11) . As shown in Fig. 2A , transient expression of the rare cutting restriction enzyme I-SceI in MCF-7 cells that carry pDR-GFP produces a DSB in one of the two GFP mutant genes (SceGFP and iGFP). The DSB can be repaired by HR between the two GFP mutant genes, resulting in the restoration of a functional GFP gene and the expression of GFP proteins. Therefore, quantification of the percentage of GFP-positive cells after expression of ISceI in MCF-7/DR-GFP cells can be used to measure the efficiency of HR-mediated DSB repair. Specifically, MCF-7/DR-GFP cells were seeded at 3 3 10 5 cells per 60 mm dish and transfected with 2.5 lg pCBASceI plasmid DNA on the following day by lipofectamine transfection (Invitrogen, Grand Island, NY). The cells and the plasmids were kindly provided by Dr. Maria Jasin at the Memorial Sloan Kettering Cancer Center. After 6 h of transfection, cells were incubated with 2.5 lM BMS and then harvested 72 h after transfection. Cells transfected with pEGFP (Clontech, Mountain View, CA) were included as a calibration control for GFP-positive cells. Cells were analyzed using a BD LSRII flow cytometer (BD Biosciences, San Jose, CA) to measure the percentage of green fluorescent cells relative to the total cell number. For each analysis, 20,000 cells were processed, and each experiment was repeated three times.
NHEJ Assay
The NHEJ assay was carried out using the EJ5-GFP reporter assay developed by Stark et al. with some modifications (12) . EJ5-GFP contains a promoter that is separated from a GFP coding region by a puro gene (Fig. 2B) . The puro gene is flanked by two I-SceI sites that are in the same orientation. Once the puro gene is removed by NHEJ repair of the two I-SceI-induced DSBs, the promoter is rejoined to the rest of the coding cassette to restore the GFP gene. Therefore, analysis of the percentage of GFP-positive cells in MCF-7 cells after cotransfection of EJ5-GFP and I-SceI can be used to measure NHEJ activity. Specifically, 3 3 10 5 MCF-7 cells were co-transfected with 2 lg of the NHEJ reporter plasmid pim-EJ5-GFP (a generous gift from Dr. Jeremy M. Stark at the City of Hope) along with 2 lg of pCBASceI (from Dr. Maria Jasin) and 0.5 lg pDsRed2-ER (Clontech) that served as a transfection control using the Fugene 6 HD transfection kit according to the manufacture's protocol (R&D Systems, Minneapolis, MN). Cells were treated with vehicle or 2.5 lM BMS at 6 h post transfection and harvested 72 h later for analysis. The percentage of GFP-expressing cells which had repaired the DSBs generated by I-SceI in the reporters by NHEJ was determined by flow cytometry in the DsRed-positive cell population after excluding dead cells by PI staining.
Microarray Gene Expression Analysis
Total RNA was isolated from MCF-7 cells after they were incubated with vehicle or 5 lM BMS for 6 h using the RNeasy Mini Kit (Qiagen, Inc., Valencia, CA). The quality and quantity of the extracted RNA were determined by the Agilent 2100 RNA 6000
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Nano Kit (Agilent Technologies, Waldbronn, Germany). All of the samples had RIN (RNA integrity number) of 9.8 or above. One hundred fifty ng of total RNA were amplified using the WTOvatione PicoSL WTA System (NuGEN Technologies, Inc., San Carlos, CA), resulting in 6-10 folds of amplification. To prepare the samples for hybridization, 3,000 ng of the amplified samples were labeled with biotin using the NuGEN Encoree BiotinIL Module. The gene expression profiling was performed using the HumanHT-12 v4 Expression BeadChip from Illumina (Illumina Inc., San Diego, CA), following the manufacturer's instructions except that the hybridization was performed using 1,500 ng at 488C per the Encore protocol. The hybridized slides were scanned using the iScan and were imported into Genespring GX11.5 (Agilent Technologies, CA). Raw data were log2 transformed and then normalized to the 75th percentile of all values on a chip. The vehicle-and BMS-treated samples were compared using t test to examine for differentially expressed genes. A list of genes with !2.0-fold change was generated first and was tested by Benjamini-Hochberg multiple testing correction. Significant genes were selected with a cut-off of P , 0.05 and a fold-change .2.0.
Ingenuity Pathway Analysis (IPA)
The selected genes were subsequently analyzed using IPA 5.0 (Ingenuity Systems Inc., Redwood, CA). Functions and pathways, which were predicted to be influenced by the differentially expressed genes, were ranked in order of significance and further analyzed by overlaying with DNA replication, recombination and repair.
Western Blot Analysis
Western blot analysis was carried out as previously reported (3) 
MTT Assay and Chou-Talalay Analysis
MCF-7 cells were seeded into 96-well plates at 5,000 cells/well. After overnight incubation, they were treated with vehicle or 2.5 or 5 lM BMS for 1 h, and then exposed to different doses (0, 1, 2 and 3 Gy) of IR. After 48 h culture, cell proliferation and viability were measured by MTT assay as previously described (13) . To determine the interactive effect between BMS treatment and IR on MCF-7 cells, Chou-Talalay analysis was performed as previously described (14) . Specifically, the dose-response curves and 50% effective dose values (ED 50 ) were obtained for the individual treatments. The fixed ratios of BMS and IR and mutually exclusive equations were used to determine the combination indices (CI) according to the method of Chou-Talalay (14) . Briefly, the combined dose-response curves were fitted to ChouTalalay lines, which are derived from the law of mass action and described by the equation: log(f a /f u ) ¼ m log(D) À m log(Dm), in which f a is the fraction affected, f u is the fraction unaffected, D is the dose, D m is the median-effect dose, and m is the coefficient signifying the shape of the dose-response curve. The CI values were calculated using the 
, where D31 and D32 are the BMS and IR doses, respectively, which are required to achieve a particular f a , and D1 and D2 are the doses of the 2 treatments (combined treatment) required for achieving the same f a . CI , 1, CI ¼ 1 and CI . 1 indicate synergistic, additive, and antagonistic interactions, respectively.
Clonogenic Survival Assay
MCF-7 cells were seeded into 12-well plates at 1,000 cells/well. After overnight incubation, they were pretreated with vehicle or 2.5 lM BMS for 1 h and then exposed to various doses (0, 1, 2 and 3 Gy) of IR. The cells were allowed to grow for an additional 12 days to form colonies before staining with 0.1% crystal purple. Colonies with more than 50 cells were counted. Survival fraction was calculated according to the plating efficiency of control cultures without BMS treatment and IR.
Analyses of Apoptosis
MCF-7 cells were seeded into 6-well plates at 5 3 10 5 /well. After overnight incubation, they were pretreated with vehicle or 5 lM BMS for 1 h and then exposed to 2 Gy of IR. They were harvested at various times after irradiation and resuspended in 13 binding buffer (BD Biosciences) at a concentration of 1 3 10 6 cells/ml. An aliquot (100 ll) of the cell suspension was incubated with 5 ll of Annexin V-FITC (BD Biosciences) or PI (1 mg/ml) for 15 min at room temperature in the dark. After addition of 400 lL of the 13 binding buffer, 10,000 cells per sample were analyzed by a BD LSR II flow cytometer (BD Biosciences) to quantify apoptotic cells (Annexin V-FITC positive cells or sub-G 1/0 cells).
MCF-7 Xenograft Tumor Model
MCF-7 xenograft tumors were established in female NCr-nu athymic nude mice (National Cancer Institute, Frederick, MD), as previously described (15) . The tumors were allowed to reach 100-150 mm 3 and the animals with tumors in this size range were randomly divided into four different treatment groups: vehicle (3% Tween 80), BMS (50 mg/kg), vehicle plus IR and BMS plus IR. Vehicle or BMS were given to mice three times by oral gavage every other day on days 1, 3 and 5. Two hours after each treatment, mice were anesthetized with isoflurane inhalation to immobilize the mice before local irradiation. Each tumor was sham-irradiated or locally irradiated by 
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3 Gy X rays generated from a Seifert Isovolt 320 X-ray machine (Seifert X-Ray, Fairview Village, PA), operated at 250 kVp and 15 mA, with 3 mm aluminum added filtration (half-value layer, 0.85 mm 3 ; dose rate, 4.49 Gy/min). The areas outside the tumor were shielded to achieve tumor-specific irradiation and to reduce damage to normal tissue. Animals for sham irradiation were placed on the irradiation stage exactly as those for irradiation, except that the X-ray machine was not turned on. All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Arkansas for Medical Sciences.
Immunohistochemistry
The athymic mice with MCF-7 xenograft tumors were pretreated with vehicle or BMS and then sham-irradiated as control or exposed to 3 Gy local IR as described above. One hour and 6 h after the exposure, the sham-irradiated and irradiated tumors were harvested after the mice were euthanized by carbon dioxide asphyxiation and cervical dislocation and fixed immediately with 4% PFA. Paraffin-embedded xenograft tumor sections were prepared in a routine manner. After antigen retrieval and permeabilization, they were stained for the analysis of c-H2AX and 53BP1 foci as described previously (3).
Statistical Analysis
The data were analyzed by analysis of variance (ANOVA). For experiments in which only single experimental and control groups were used, group differences were examined by unpaired Student t test. Differences were considered significant at P , 0.05. All of these analyses were carried out using GraphPad Prism from GraphPad Software (San Diego, CA).
RESULTS
BMS Inhibits the Repair of IR-Induced DSBs in a DoseDependent Manner
BMS is a potent and specific IKKb inhibitor (7) and can dose-dependently inhibit IR-induced NF-jB activation in MCF-7 cells, as shown in Fig. 1A . This inhibition was correlated with a dose-dependent reduction in the repair of IR-induced DSBs analyzed by the c-H2AX and 53BP1 foci assays 6, 12 and 24 h after irradiation (Fig. 1B and C) (16) (17) (18) . This finding was validated by the neutral comet assay ( Fig. 1D and E) (19) , and confirmed that BMS can effectively inhibit the repair of IR-induced DSBs in MCF-7 cells. Similar findings were also observed in other tumor cell lines (data not shown).
BMS Selectively Inhibits HR
DSBs can be repaired by HR and/or NHEJ (20, 21) . To gain more insight into the mechanisms by which BMS inhibits DSB repair, we employed the DR-GFP and EJ5-GFP reporter assays to measure HR and NHEJ (11, 12) , respectively ( Fig. 2A and B) . It was found that BMS treatment significantly decreased the percentage of GFPpositive cells in MCF-7/DR-GFP cells after expression of ISceI in comparison with the cells without BMS treatment (Fig. 2C and D) . In contrast, the percentage of GFP-positive cells in MCF-7 cells co-transfected with the EJ5-GFP and ISceI plasmids was slightly increased after BMS treatment ( Fig. 2C and E) . These findings suggest that BMS can selectively inhibit the repair of DSBs induced by I-SceI by the HR pathway.
To determine whether BMS also inhibits the repair of IRinduced DSBs through the inhibition of HR, we compared the formation of IR-induced Rad51 and Brca1 foci in MCF-7 cells treated with vehicle or BMS. The assembly of Rad51 nucleoprotein filament (or foci) represents an important step in the repair of DSBs by HR and Brca1 is required for the formation of Rad51 foci (21, 22) . As shown in Fig. 2F and G, 1 h after exposure to IR vehicle-treated MCF-7 cells exhibited significant increases in the formation of Brca1 and Rad51 foci. The increases were diminished by the treatment with BMS, even though BMS-treated MCF-7 cells exhibited similar numbers of c-H2AX and 53BP1 foci after irradiation at the same time point (Fig. 1B and C) . These data provide further support that BMS can selectively inhibit HR.
BMS Inhibits the Expression of Several Genes that are Involved in HR
To gain a better understanding of how BMS inhibits HR, we compared the gene expression profiles of MCF-7 cells treated with vehicle or BMS by microarray assay. Genesping GX analysis revealed about 869 genes altered greater than twofold (P , 0.05) in the BMS-treated cells compared to vehicle-treated cells (supplementary material Table S2 : http://dx.doi.org/10.1667/RR3034.1.S2). Among these genes, 146 were up-regulated and 723 were down-regulated as shown in Fig. 3A . Particularly, IPA identifies that BMS treatment compromised the DNA damage repair and response pathway (Fig. 3B ) and the cell cycle control pathway (Fig. 3C) . Very interestingly, 5 of the downregulated genes in the DNA damage repair and response pathway (supplementary material Table S3 : http://dx.doi. org/10.1667/RR3034.1.S3), BARD1, PALB2, EXO1, RAD54B and SIRT1, have been implicated in HR (23) (24) (25) (26) . Their down-regulation was confirmed by qRT-PCR (Fig.  3D) . It has been shown that Bard1 is required for proper localization of Brca1 to the sites of DSBs (25) and that Exo1 is required for the recruitment of RPA and Rad51 to DSBs (23), whereas Brca1/Brca2 and Palb2 act together to facilitate the assembly of Rad51 nucleoprotein filament (or foci) (26) . In addition, it was reported recently that Sirt1 can promote HR repair of DSBs by interacting with the WRN helicase (24) . Therefore, it is highly plausible that by downregulating these HR genes, BMS may effectively inhibit the repair of DSBs by HR.
To determine whether inhibition of IKKb and NF-jB mediates BMS-induced suppression of HR gene expression, we examined the effects of IKKb knockdown by shRNA and inhibition of NF-jB by a dominant-negative mutant IjBa (mIjBa) on the expression of BARD1, PALB2, EXO1, RAD54B and SIRT1 mRNA in MCF-7 cells. As shown in Fig. 3E , we found that knockdown of IKKb by a 164 specific IKKb shRNA down-regulated the expression of BARD1, PALB2, EXO1, RAD54B and SIRT1 mRNA. In contrast, ectopic expression of mIjBa that inhibits NF-jB activity had no such effect (Fig. 3E) . These findings suggest that inhibition of IKKb may mediate BMS-induced suppression of HR gene expression, but in an NF-jBindependent manner. The mechanisms whereby IKKb regulates these HR genes have yet to be determined.
BMS Increases DNA Damage Response to IR
Cells respond to DNA damage by eliciting a series of cellular responses collectively termed the DNA damage response (DDR) (27) . DDR can be initiated by IR through ATM that functions as a part of the DNA damage sensory machinery to detect DSBs (28) . After the recruitment to the sites of DSBs, ATM is phosphorylated and activated. Activated ATM in turn phosphorylates a number of substrates, including Chk2 and p53, to induce cell-cycle arrest and facilitate DNA repair. If the damage cannot be repaired promptly and efficiently, it can lead to sustained activation of DDR and induction of cell death. Since BMS inhibits the repair of IR-induced DSBs in MCF-7 cells, we hypothesized that BMS may sensitize the cells to IR by augmenting DDR. To test this hypothesis, we examined the magnitude and duration of ATM and Chk2 phosphorylation/activation in MCF-7 cells after they were exposed to IR 
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in the presence or absence of BMS by immunofluorescent staining. As shown in Figs. 4A-C, exposure to IR increased the numbers of pATM foci and pChk2 foci in MCF-7 cells and the increases were comparable in MCF-7 cells treated with vehicle or BMS 1 h after IR when the formation of the foci reached the peak level. The numbers of pATM and pChk2 foci in vehicle-treated cells declined rapidly thereafter and were almost back to the basal levels at 6 h after irradiation, because these cells could efficiently repair IR-induced DSBs. In contrast, the numbers of pATM and pChk2 foci in BMS-treated cells remained significantly elevated 6 h after irradiation due to an inability of the cells to efficiently repair DSBs. Similar finding was also observed when we analyzed p53 phosphorylation as an additional indicator of DDR by Western blot (Fig. 4D) . These findings suggest that BMS treatment not only inhibits the repair of IR-induced DSBs in MCF7 cells but also elicits a stronger and more sustained DDR to IR.
BMS Sensitizes MCF-7 Cells to IR in an ApoptosisIndependent Manner
It has been well-established that IR kills cancer cells primarily by induction of DSBs and efficient repair of DSBs is required for the survival of irradiated cells (1, 2). Since BMS can inhibit the repair of IR-induced DSBs and augment DDR in MCF-7 cells, we hypothesized that BMS may sensitize the cells to IR. This hypothesis was confirmed by the finding that BMS pretreatment significantly reduced the proliferation and survival after MCF-7 cells were exposed to increasing doses of IR measured by MTT assay (Fig. 5A) . The interaction between BMS and IR was synergistic (CI , 1) according to the Chou-Talalay analysis (14) . In addition, the clonogenic survival assay demonstrated that MCF-7 cells treated with BMS were more sensitive to IR-induced clonogenic cell death than were the cells without BMS treatment (Fig. 5B-D) .
It has been assumed that inhibition of the IKK-NF-jB pathway increases the sensitivity of many types of tumor cells to IR and chemotherapy primarily via inhibition of the expression of anti-apoptotic proteins (4, 6, 29, 30) . To rule out this possibility, we analyzed apoptosis in irradiated MCF-7 cells treated with vehicle or BMS by Annexin V staining and sub G 0/1 cell analysis and found that MCF-7 cells were highly resistant to IR-induced apoptosis (Fig. 5E  and F ). This finding is in agreement with those reported previously (31), because MCF-7 cells are deficient in caspase 3 expression and insensitive to the induction of 
BMS Sensitizes MCF-7 Xenograft Tumors to IR
Since BMS can sensitize MCF-7 cells to IR in vitro, next we examined whether BMS can also sensitize MCF-7 cells to IR in vivo in a xenograft tumor mouse model. As shown in Fig. 6A , MCF-7 xenograft tumors grew rapidly in nude mice if the mice and tumor were not treated with BMS and irradiation. These untreated mice had to be humanly euthanized 30 days after the initiation of the experiment to reduce unnecessary pain associated with large tumors (.1,500 mm 3 ). Exposure of the tumors to 3 fractionated and local X-ray irradiations or the administration of BMS to the mice slightly retarded the growth of the tumors (P , 0.001). However, the growth of the tumors was more significantly inhibited by the combined treatment with BMS and IR than of those treated with either BMS or IR alone (P , 0.001).
This finding was confirmed when the tumors were dissected and compared at the end of the experiment (Fig. 6B) .
To examine whether the increased inhibition of MCF-7 tumor growth by the combined treatment with BMS and IR can be partially attributed to BMS-mediated inhibition of DSB repair, we analyzed the numbers of c-H2AX and 53BP1 foci in tumors from control untreated mice and those at 1 and 6 h after exposure of the tumors to IR from mice pretreated with BMS or vehicle. As expected, tumors without exposure to IR exhibited very few c-H2AX and 53BP1 foci (Fig. 6C and D) . The numbers of these foci increased in a similar degree at 1 h after irradiation in the tumors from BMS-or vehicle-treated mice. At 6 h after irradiation, the majority of the foci had disappeared in the tumors from vehicle-treated mice due to a rapid repair of IRinduced DSBs. However, the tumors from BMS-treated mice exhibited a significant delay in the repair of the DNA damage (P , 0.001). This observation confirms that BMS treatment also inhibits tumor cell repair of IR-induced DSBs in vivo. 
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DISCUSSION
Ionizing radiation is one of the most widely used therapeutic modalities for cancer. Unfortunately, some tumor cells are inherently more resistant to IR or can acquire radioresistance shortly after radiotherapy, in part due to activation of the IKK NF-jB pathway (29) . Therefore, inhibition of the IKK NF-jB pathway has the potential to increase the therapeutic index of radiotherapy (29) . Among various inhibitors of the IKK NF-jB pathway, IKKb inhibitors have emerged as the most promising antitumor agents and novel tumor sensitizers for IR and chemotherapy (32) . However, the mechanisms of their action have not been well studied, but are presumably attributed to the inhibition of NF-jB activity, which can increase tumor cell apoptosis by reducing the expression of anti-apoptotic proteins (4, 6, 29, 30) . The results from our recent studies revealed that IKKb inhibitors, including BMS, can also inhibit the repair of IR-induced DSBs (3). More importantly, in the present study we showed that BMS could selectively inhibit HR most likely via downregulation of several genes that participate in HR. This could lead to sensitization of MCF-7 cells to IR by augmenting IR-induced DDR but would be independent of the induction of apoptosis.
It has been suggested that tumor cells may preferentially depend on HR to repair DSBs compared with normal cells (34) . Therefore, tumor cells may be more sensitive to the inhibition of the HR pathway by BMS than normal tissues. This suggestion is in agreement with the findings that BMS is a relatively safe agent that does not cause noticeable normal tissue damage in vivo (8-10), but is highly toxic to some tumor cells (34) (35) (36) and can selectively sensitize MCF-7 cells (3), but not mouse bone marrow hematopoietic progenitor cells, to IR in vitro (data not shown). In addition, our previous studies showed that BMS is almost equally potent as are the commonly used DNA-PK inhibitor NU7026 and ATM inhibitor KU55933 in inhibition of the repair of IR-induced DSBs (3). Furthermore, since BMS can 
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inhibit not only the repair of DSBs, but also NF-jBmediated induction of anti-apoptotic proteins (4-6), it is potentially more advantageous than these other DSB repair inhibitors as a tumor radiosensitizer. However, the mechanisms by which BMS can selectively inhibit HR by down-regulating the expression of various HR genes remain to be elucidated. Since our previous studies showed that NF-jB-RelA is dispensable for IKKbdependent regulation of DSB repair (3), BMS may regulate HR gene expression by a non-IjB/NF-jB target of IKKb (37) . This hypothesis is supported by the finding that knockdown of IKKb by a specific IKKb shRNA downregulated the expression of selective HR genes. In contrast, ectopic expression of a nondegradable IjBa mutant that inhibits NF-jB activity had no such effect. We anticipate that the identification of the specific IKKb substrate(s) required for DSB repair and elucidation of the mechanisms by which BMS regulates the expression of HR genes and DSB repair will likely reveal novel targets for cancer therapy, which will be investigated in our future studies.
